Clinical Trials Tracker
Clinical Trials Tracker: Ketamine & Esketamine Studies
Registered studies are the earliest public signal of where ketamine research is heading. These listings come straight from the U.S. registry — Ketalux does not edit, rank, or summarize study results here.
Written by: Ira ZootMedical review status: Not yet clinically reviewed.Last updated: August 28, 2026Evidence: ClinicalTrials.gov registry data
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
Quick answer
Does appearing in a clinical trial mean a treatment works?
No. Registration means a study has been planned and listed with a public registry. It says nothing about whether the intervention is safe or effective for the condition being studied — those conclusions require completed, peer-reviewed results.
Source and freshness
Listings are retrieved live from the ClinicalTrials.gov API each time you load this page. Always confirm eligibility, status, and contact details on the official study record before acting on anything here.
What these listings are — and are not
- A listing is a registration, not a result. It records that a study was planned and described publicly. Findings, if any, appear later in the registry's results section or in peer-reviewed publications.
- Recruitment status is not evidence. "Recruiting" means enrollment is open; it says nothing about safety, effectiveness or how the study will turn out.
- Ketalux does not endorse any trial, sponsor, investigator, site or provider shown here. Listings are reproduced as published by the registry, with no selection for or against any organization, and Ketalux has no financial or referral relationship with them.
- The data comes from ClinicalTrials.gov, the U.S. National Library of Medicine registry, through its public API. Ketalux does not edit, correct, estimate or add to the fields returned; blank fields are shown as "Not stated".
- "Data as of" is a retrieval timestamp, recording when this page last received data from the registry — not when a study changed and not when this page was edited.
- If the registry cannot be reached, the last successfully retrieved snapshot is shown unchanged, clearly labelled, with its own earlier retrieval time.
Data as of: — registry retrieval time. This is separate from the page's editorial last-updated date above.
- RECRUITINGUpdated 2026-09-03
The OBSERVE Protocol
- Conditions:
- Major Depression Disorder
- Interventions:
- Spravato, IV Ketamine
- Sponsor:
- Yale University
- Enrollment:
- 450 participants
- Start:
- 2024-01-21
- Primary completion:
- 2029-12
- Locations:
- Milford, Connecticut, United States · New Haven, Connecticut, United States · Atlanta, Georgia, United States · Ann Arbor, Michigan, United States
- Identifier:
- NCT06725277
- RECRUITINGPHASE2Updated 2026-09-02
Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients
- Conditions:
- Critical Illness, Depressive Symptoms
- Interventions:
- Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
- Sponsor:
- Hospital Italiano de Buenos Aires
- Enrollment:
- 50 participants
- Start:
- 2026-05-14
- Primary completion:
- 2028-05-01
- Locations:
- Jacksonville, Florida, United States · Buenos Aires, Buenos Aires, Argentina
- Identifier:
- NCT07639359
- RECRUITINGNAUpdated 2026-09-02
Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2
- Conditions:
- Ischemic Stroke, Anterior Cerebral Circulation, General Anesthesia, Procedural Sedation, Thrombectomy
- Interventions:
- General Anesthesia, Procedural sedation
- Sponsor:
- University Hospital, Clermont-Ferrand
- Enrollment:
- 958 participants
- Start:
- 2026-03-24
- Primary completion:
- 2029-06-24
- Locations:
- Angers, France · Brest, France · Clermont-Ferrand, France · Lille, France
- Identifier:
- NCT07235514
- RECRUITINGPHASE2Updated 2026-09-02
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
- Conditions:
- Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
- Interventions:
- Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion
- Sponsor:
- Mohsen Saidinejad
- Enrollment:
- 120 participants
- Start:
- 2026-09-10
- Primary completion:
- 2027-12-31
- Locations:
- Torrance, California, United States
- Identifier:
- NCT07369024
- RECRUITINGPHASE2Updated 2026-09-01
Neurobiology of Suicide
- Conditions:
- Healthy Volunteers, Depression
- Interventions:
- Magnetic Resonance Imaging scanner, 3T, NeurOptics PLRTM-3000 Pupillometer, Experimental Anxiety Devices, Magnetic Resonance Imaging scanner, 7T, Ketamine Hydrochloride
- Sponsor:
- National Institute of Mental Health (NIMH)
- Enrollment:
- 325 participants
- Start:
- 2015-12-01
- Primary completion:
- 2030-07-21
- Locations:
- Bethesda, Maryland, United States
- Identifier:
- NCT02543983
- RECRUITINGPHASE1Updated 2026-09-01
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
- Conditions:
- Healthy Volunteer, Major Depressive Disorder, Depression
- Interventions:
- Ketamine, Placebo, Cobot TS MV robotic arm for TMS, NeurOptics PLRTM-30000 Pupillometer
- Sponsor:
- National Institute of Mental Health (NIMH)
- Enrollment:
- 150 participants
- Start:
- 2017-05-25
- Primary completion:
- 2027-01-01
- Locations:
- Bethesda, Maryland, United States
- Identifier:
- NCT03065335
- RECRUITINGNAUpdated 2026-08-31
Effect of Esketamine on Postoperative Sleep in Postmenopausal Women
- Conditions:
- Circadian Rhythm, Postoperative Sleep Disturbance
- Interventions:
- Esketamine, Normal Saline
- Sponsor:
- Zhuan Zhang
- Enrollment:
- 164 participants
- Start:
- 2026-03-01
- Primary completion:
- 2026-12-31
- Locations:
- Jingjiang, Jiangsu, China · Yangzhou, Jiangsu, China
- Identifier:
- NCT07315074
- RECRUITINGPHASE2Updated 2026-08-31
Ketamine for Opioid Use Disorder
- Conditions:
- Opioid Use Disorder
- Interventions:
- Treatment with Ketamine, Treatment with Very Low Dose Ketamine
- Sponsor:
- University of Maryland, Baltimore
- Enrollment:
- 50 participants
- Start:
- 2026-02-04
- Primary completion:
- 2028-08-31
- Locations:
- Baltimore, Maryland, United States
- Identifier:
- NCT06943859
- RECRUITINGNAUpdated 2026-08-28
Efficacy of Esketamine for Patients With Irritable Bowel Syndrome
- Conditions:
- Irritable Bowel Syndrome
- Interventions:
- The colonoscopy, Esketamine
- Sponsor:
- Beijing Tiantan Hospital
- Enrollment:
- 552 participants
- Start:
- 2025-02-08
- Primary completion:
- 2026-12-31
- Locations:
- Beijing, Beijing Municipality, China
- Identifier:
- NCT06788444
- RECRUITINGPHASE3Updated 2026-08-28
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
- Conditions:
- Depressive Disorder, Treatment-Resistant
- Interventions:
- Esketamine 56 mg, Esketamine 84 mg, Placebo
- Sponsor:
- Janssen Research & Development, LLC
- Enrollment:
- 348 participants
- Start:
- 2026-07-23
- Primary completion:
- 2028-12-27
- Locations:
- Redlands, California, United States · Skokie, Illinois, United States · New York, New York, United States · Kawasaki, Japan
- Identifier:
- NCT07716098
- RECRUITINGPHASE3Updated 2026-08-28
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Conditions:
- Depressive Disorder, Major
- Interventions:
- Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
- Sponsor:
- Janssen Research & Development, LLC
- Enrollment:
- 258 participants
- Start:
- 2026-01-08
- Primary completion:
- 2031-04-09
- Locations:
- Birmingham, Alabama, United States · Washington D.C., District of Columbia, United States · Atlanta, Georgia, United States · Evanston, Illinois, United States
- Identifier:
- NCT07227454
- RECRUITINGPHASE2Updated 2026-08-27
KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury
- Conditions:
- PTSD and Trauma-related Symptoms
- Interventions:
- Preparatory Session, Ketamine-assisted Psychotherapy Session #1, Ketamine-assisted Psychotherapy Session #2, Integration Session
- Sponsor:
- Irma Fleming
- Enrollment:
- 12 participants
- Start:
- 2026-08-24
- Primary completion:
- 2027-12-01
- Locations:
- Salt Lake City, Utah, United States
- Identifier:
- NCT07563296
- RECRUITINGNAUpdated 2026-08-26
Opioid-free Anesthesia as an Alternative to General Anesthesia in Abdominal Surgery
- Conditions:
- Analgesics, Opioid, Anesthesia, Endotracheal, Anesthesia, General
- Interventions:
- anesthesia without opioids
- Sponsor:
- Jagiellonian University
- Enrollment:
- 600 participants
- Start:
- 2024-04-29
- Primary completion:
- 2026-12-31
- Locations:
- Krakow, Lesser Poland Voivodeship, Poland
- Identifier:
- NCT06380244
- RECRUITINGNAUpdated 2026-08-19
Cognitive Training as an Adjunct to Ketamine in Real-world Clinics
- Conditions:
- Depression
- Interventions:
- Cognitive Training, Sham Training
- Sponsor:
- University of Pittsburgh
- Enrollment:
- 600 participants
- Start:
- 2024-11-12
- Primary completion:
- 2029-05-31
- Locations:
- Oakland, California, United States · Chicago, Illinois, United States · Houston, Texas, United States
- Identifier:
- NCT06526078
- RECRUITINGNAUpdated 2026-08-17
Ketamine Infusion as a Method of Cerebral Protection in Children
- Conditions:
- Brain Injuries
- Interventions:
- Ketamine Hcl 50Mg/Ml Inj, Ketamine Hcl 50Mg/Ml Inj, Control
- Sponsor:
- Kemerovo State Medical University
- Enrollment:
- 196 participants
- Start:
- 2023-11-05
- Primary completion:
- 2028-12-30
- Locations:
- Kemerovo, Please Select, Russia
- Identifier:
- NCT06525584
- RECRUITINGPHASE1Updated 2026-08-17
Glutamatergic Mechanisms: Aim2
- Conditions:
- Healthy
- Interventions:
- Ketamine, Ts-134 or XT, Placebo
- Sponsor:
- New York State Psychiatric Institute
- Enrollment:
- 120 participants
- Start:
- 2022-10-15
- Primary completion:
- 2028-08
- Locations:
- New York, New York, United States
- Identifier:
- NCT05401227
- RECRUITINGPHASE3Updated 2026-08-13
InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression
- Conditions:
- Treatment Resistant Depression
- Interventions:
- Ketamine, Oculus VR headset
- Sponsor:
- Sunnybrook Health Sciences Centre
- Enrollment:
- 31 participants
- Start:
- 2026-05-03
- Primary completion:
- 2027-12
- Locations:
- Toronto, Ontario, Canada
- Identifier:
- NCT06781697
- RECRUITINGPHASE4Updated 2026-08-12
Positioning of Esketamine Treatment in the Real-world Management of Depression
- Conditions:
- Major Depressive Disorder
- Interventions:
- Esketamine Nasal Spray [Spravato]
- Sponsor:
- Royal North Shore Hospital
- Enrollment:
- 162 participants
- Start:
- 2023-10-31
- Primary completion:
- 2027-12-15
- Locations:
- St Leonards, New South Wales, Australia
- Identifier:
- NCT06103760
- RECRUITINGPHASE1PHASE2Updated 2026-08-12
Pilot Study of RR-HNK in OCD
- Conditions:
- Obsessive-Compulsive Disorder
- Interventions:
- RR-HNK/Hydroxynorketamine, Placebo
- Sponsor:
- Carolyn Rodriguez
- Enrollment:
- 45 participants
- Start:
- 2026-01-23
- Primary completion:
- 2028-11-30
- Locations:
- Palo Alto, California, United States
- Identifier:
- NCT06575075
- RECRUITINGPHASE2Updated 2026-08-06
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Conditions:
- Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
- Interventions:
- ACP-211, Placebo
- Sponsor:
- ACADIA Pharmaceuticals Inc.
- Enrollment:
- 153 participants
- Start:
- 2025-11-14
- Primary completion:
- 2027-08
- Locations:
- Birmingham, Alabama, United States · Chino, California, United States · Glendale, California, United States · La Jolla, California, United States
- Identifier:
- NCT07284667
- RECRUITINGPHASE4Updated 2026-08-05
Opioid Free Anesthesia on the Quality of Early Recovery
- Conditions:
- Opioid-free Anesthesia
- Interventions:
- OFA group (group T)
- Sponsor:
- Beijing Friendship Hospital
- Enrollment:
- 160 participants
- Start:
- 2024-08-01
- Primary completion:
- 2026-10-01
- Locations:
- Beijing, Beijing Municipality, China
- Identifier:
- NCT05577962
- RECRUITINGUpdated 2026-08-05
Anesthetics and Analgesics in Children
- Conditions:
- Anesthesia, Pain
- Interventions:
- Ketorolac Tromethamine, Hydromorphone, Ketamine, Oxycodone, Morphine
- Sponsor:
- Chi Dang Hornik
- Enrollment:
- 551 participants
- Start:
- 2018-12-13
- Primary completion:
- 2027-08-30
- Locations:
- Stanford, California, United States · Aurora, Colorado, United States · Wilmington, Delaware, United States · Chicago, Illinois, United States
- Identifier:
- NCT03427736
- RECRUITINGEARLY PHASE1Updated 2026-08-04
Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
- Conditions:
- Major Depressive Disorder (MDD)
- Interventions:
- Ketamine only
- Sponsor:
- University of Pennsylvania
- Enrollment:
- 10 participants
- Start:
- 2026-04-01
- Primary completion:
- 2026-09-15
- Locations:
- Philadelphia, Pennsylvania, United States
- Identifier:
- NCT06788249
- RECRUITINGPHASE1PHASE2Updated 2026-08-03
(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain
- Conditions:
- Pain, Neuropathic
- Interventions:
- Ketamine, (2R,6R)-hydroxynorketamine, Saline
- Sponsor:
- Rush University Medical Center
- Enrollment:
- 25 participants
- Start:
- 2024-09-19
- Primary completion:
- 2027-04
- Locations:
- Chicago, Illinois, United States
- Identifier:
- NCT05864053
- RECRUITINGPHASE3Updated 2026-07-31
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
- Conditions:
- Depression
- Interventions:
- Racemic ketamine, Spravato (Esketamine)
- Sponsor:
- Yale University
- Enrollment:
- 400 participants
- Start:
- 2025-01-27
- Primary completion:
- 2030-12-31
- Locations:
- Milford, Connecticut, United States · New Haven, Connecticut, United States · Atlanta, Georgia, United States · Ann Arbor, Michigan, United States
- Identifier:
- NCT06713616
How to read a trial listing
Phase matters: Phase 1 studies test safety in small groups, Phase 2 looks for early signals of effect, and Phase 3 tests effectiveness against a comparator at scale. Recruitment status tells you whether enrollment is open, not whether the study has produced results. For published results, see the Research Library; for regulatory context, see the Regulatory Tracker.
Considering a trial?
Trial participation is a medical decision. Discuss any study with your own clinician, and review the study's eligibility criteria and risks on the official record before contacting a site.
About the author
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.